ArticleBioengineering (Basel, Switzerland)2024
Automatic Detection of Acute Leukemia (ALL and AML) Utilizing Customized Deep Graph Convolutional Neural Networks.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Deep Learning-Based Automatic Segmentation of Ischemic Stroke Lesions in CT Perfusion Imaging.Biomimetics (Basel, Switzerland) · 2026Article
- Acute Myeloid Leukemia subtype classification using single blood cell images.Discover oncology · 2025Article
- Advancements in Hematologic Malignancy Detection: A Comprehensive Survey of Methodologies and Emerging Trends.TheScientificWorldJournal · 2025Review
- An explainable deep learning-based feature fusion model for acute lymphoblastic leukemia diagnosis and severity assessment.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is a malignant disease that impacts explicitly the blood cells, leading to life-threatening infections and premature mortality. State-of-the-art machine-enabled technologies and sophisticated deep learning algorithms can assist clinicians in early-stage disease diagnosis. This study introduces an advanced end-to-end approach for the automated diagnosis of acute leukemia classes acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). This study gathered a complete database of 44 patients, comprising 670 ALL and AML images. The proposed deep model's architecture consisted of a fusion of graph theory and convolutional neural network (CNN), with six graph Conv layers and a Softmax layer. The proposed deep model achieved a classification accuracy of 99% and a kappa coefficient of 0.85 for ALL and AML classes. The suggested model was assessed in noisy conditions and demonstrated strong resilience. Specifically, the model's accuracy remained above 90%, even at a signal-to-noise ratio (SNR) of 0 dB. The proposed approach was evaluated against contemporary methodologies and research, demonstrating encouraging outcomes. According to this, the suggested deep model can serve as a tool for clinicians to identify specific forms of acute leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.